Matthew Hawryluk Predictive Oncology Inc. (POAI) insider trading activity

Matthew Hawryluk is Director of Predictive Oncology Inc.. Currently has a direct ownership of 74,168 shares of POAI, which is worth approximately $661,578. The most recent transaction as insider was on Sep 09, 2025, when has been sold 64,680 shares (Common Stock) at a price of $0.0 per share, resulting in proceeds of $0. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 74.2K

681.7% 3M change

681.7% 12M change

Total Value Held $661,578

Matthew Hawryluk Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Sep 09 2025	BUY Grant, award, or other acquisition	-	64,680 Added 46.58%	74,168 Common Stock
Apr 05 2024	BUY Grant, award, or other acquisition	-	2,368 Added 19.97%	9,488 Common Stock
Oct 02 2023	BUY Grant, award, or other acquisition	-	1,875 Added 20.81%	7,135 Common Stock
Jul 03 2023	BUY Grant, award, or other acquisition	-	2,675 Added 33.71%	5,260 Common Stock
Apr 03 2023	BUY Grant, award, or other acquisition	-	18,360 Added 26.21%	51,692 Common Stock
Jan 03 2023	BUY Grant, award, or other acquisition	-	19,570 Added 36.99%	33,332 Common Stock
Dec 01 2022	BUY Grant, award, or other acquisition	-	13,762 Added 50.0%	13,762 Common Stock

Also insider at

GRTS

Gritstone bio, Inc. Healthcare

EVP, CHIEF BUSINESS OFFICER